J&J opens the valve on $50M MS partnership with Pipeline

Johnson & Johnson is turning on the tap for Pipeline Therapeutics in a $50 million upfront licensing deal for an oral multiple sclerosis drug that could net the small biotech up to $1 billion down the line.